Determine levels of fibrosis and necroinflammatory activity
Our robust menu of biomarker testing assesses liver disease related to nonalcoholic and alcoholic causes. These include FibroTest-ActiTest, a first-line screening assay that uses two diagnostic scores based on component tests for six biomarkers to assess the liver for nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH)-FibroTest, which evaluates 10 biomarkers to assess liver condition; and direct alcohol biomarker testing, which assesses the blood for alcohol use.
FibroTest-ActiTest assesses the liver for fibrosis and inflammation using two diagnostic scores based on component testing of six biomarkers. It is the most reliable biomarker test available, applies to the largest number of patients (98%),4 and outperforms other testing at all stages of fibrosis.5
Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
NASH, steatosis, and fibrosis/cirrhosis testing
Using a simple blood sample, our nonalcoholic steatohepatitis FibroTest combines 10 standard biomarkers into five scores to provide a complete assessment of the liver condition and the five main causes of liver disease, including hepatic steatosis, NASH, alcoholic steatohepatitis, fibrosis, and liver inflammation.
Confirms diagnosis and monitoring of liver fibrosis, steatosis, and inflammation.
Useful for estimating hepatic fibrosis.
Assesses inflammation of metabolic disease.
Assesses severity of NASH in patients with NAFLD, as well as steatosis or fatty liver.
View nowTest reports combine 10 standard biomarkers into five scores
Alcoholic liver disease confirmation and monitoring
Diagnosing individuals with alcoholic liver disease, which encompasses a spectrum of liver injury, often requires a history of significant alcohol intake, clinical evidence of liver disease, and supporting laboratory testing.7 Our menu of direct ethanol biomarker testing accurately assesses alcohol use and includes direct biomarker testing, which enables detection of even small amounts of ethanol eliminated via non-oxidative pathways into ethyl glucuronide (EtG), ethyl sulfate (EtS), and phosphatidylethanol (PEth).8
Benefits of biomarker testing include improved analysis of the specific role alcohol plays in an individual’s health; clarity on the actual amounts of recent consumption, which, combined with questionnaires, can support initiating clinical interventions; and verification and monitoring of ethanol abstinence in liver transplant candidates/patients.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Dec;23(47):8263-8276.
Marengo A, Jouness RIK, Bugianesi E. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis. 2016;20(2):G313–G324. doi:10.1016/j.cld.2015.10.010
Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol. 2011;11:39. doi:10.1186/1471-230X-11-39
Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 2016;43:1.
Poynard T, de Ledinghen V, Zarski JP, et al. Performances of Elasto-FibroTest,® a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2012;36(5):455-63.